http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104968347-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e6f10141ac5f791e5b04c0489b69a95e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2013-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e7dba1fa34337765d76c11b3d9f44e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74dab7d657686e608dd089042eb00dc9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be0cfaab84686f2e24db6eb6c4573b13 |
| publicationDate | 2015-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104968347-A |
| titleOfInvention | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
| abstract | The present invention relates to a method for treating patients afflicted with cancer, wherein said patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and the optional at least one antineoplastic agent, are administered in a dosage regimen that comprises a therapeutically effective amount. The present invention also relates to methods for predicting therapeutic response to said treatment in a given patient and therefore identification of applicable patient subpopulations based upon these predictor factors; sometimes referred to as biomarkers. One method is based upon the clinical marker of pain intensity. The second method is based upon gene expression predictive biomarkers assessed via RNA expression in peripheral blood cell samples collected prior to treatment with a compound of the invention (i.e. a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, especially masitinib). Advantageously, the present invention relates to a method for treating patients afflicted with pancreatic cancer wherein said patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and in particular masitinib, optionally in combination with at least one antineoplastic agent, and in particular gemcitabine. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111759857-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110381938-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108883108-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108883108-B |
| priorityDate | 2012-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 773.